7 KILLED, HUNDREDS INJURED AS STRONG QUAKE HITS SULAWESI, INDONESIA
VATICAN: POPE FRANCIS, FORMER POPE BENEDICT BOTH GET COVID-19 VACCINE
AUSTRALIA REBUKES GOOGLE FOR BLOCKING LOCAL CONTENT
JAPAN TO BAN ENTRY OF FOREIGN ATHLETES TO TRAIN AHEAD OF SUMMER OLYMPICS
BIDEN INAUGURATION WILL FEATURE DIVERSE PERFORMANCES INCLUDING LADY GAGA, JENNIFER LOPEZ
COURT ORDERS ARREST OF COPS ACCUSED OF KILLING ARMY MEN IN JOLO
THE PANDEMIC SLAMS PHL VEHICLE SALES IN 2020
CHESS PLAYER WESLEY SO BAGS P11.8M, JOINS WORLD’S TOP ESPORT EARNERS
ZSA ZSA PADILLA FINALLY VISITS THE GRAVE OF ‘COMEDY KING’ DOLPHY AGAIN
DUTERTE: PRESIDENCY JOB NOT FOR A WOMEN

CHINA’S CANSINO DEFENDS COVID-19 VACCINE CANDIDATE AFTER EXPERTS CAST DOUBT

7 months ago | World Science & Technology News | 0 comments

By Xai Reyes

China’s CanSino Biologics said on Wednesday (Sept 9) that expert opinion on its high-profile COVID-19 vaccine candidate should not be followed “blindly” without sufficient clinical trial data.

Scientists outside the company have expressed concern that the effectiveness of CanSino’s candidate Ad5-nCoV, which is based on a common cold virus to which many people have been exposed, could be limited.

They said existing antibodies against the common cold virus might undermine Ad5-nCoV.

“Vaccine development is a practice-based science, and we should not blindly follow experts,” Zhu Tao, chief scientific officer.

0 Comments

Submit a Comment

Your email address will not be published.

Social Media